,
,
, , vol.86
,
WHO classification of tumours of haematopoietic and lymphoid tissues, 2008. ,
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia, Blood. 4 juin, vol.125, issue.23, pp.3618-3644, 2015. ,
Myelomonocytic leukemia: Disorderly proliferation of all marrow cells, Cancer. 1 mai, vol.27, issue.5, pp.1221-1251, 1971. ,
DOI : 10.1002/1097-0142(197105)27:5<1221::aid-cncr2820270530>3.0.co;2-p
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/1097-0142%28197105%2927%3A5%3C1221%3A%3AAID-CNCR2820270530%3E3.0.CO%3B2-P
Chronic Myelomonocytic Leukaemia, Br J Haematol. 1 juill, vol.30, issue.3, pp.289-302, 1975. ,
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group, Br J Haematol. août, vol.33, issue.4, pp.451-459, 1976. ,
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features, Leukemia. juill, vol.22, issue.7, pp.1308-1327, 2008. ,
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia, Blood, vol.17, issue.16, pp.2807-2811, 2013. ,
DOI : 10.1182/blood-2013-03-491399
URL : http://www.bloodjournal.org/content/122/16/2807.full.pdf
Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature, J Clin Pharm Ther. 1 août, vol.31, issue.4, pp.401-407, 2006. ,
Cytogenetic risk stratification in chronic myelomonocytic leukemia, Haematologica. mars, vol.96, issue.3, pp.375-83, 2011. ,
DOI : 10.3324/haematol.2010.030957
URL : http://www.haematologica.org/content/96/3/375.full.pdf
Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization, Clin Lymphoma Myeloma Leuk. juin, vol.15, pp.50-55, 2015. ,
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes, Leukemia. 1 juill, vol.27, issue.7, pp.1504-1514, 2013. ,
DOI : 10.1038/leu.2013.88
URL : https://www.nature.com/articles/leu201388.pdf
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance, Am J Hematol. mars, vol.88, issue.3, pp.201-207, 2013. ,
DOI : 10.1002/ajh.23373
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.23373
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A, Blood, vol.118, issue.14, pp.3932-3973, 2011. ,
DOI : 10.1182/blood-2010-10-311019
URL : http://www.bloodjournal.org/content/118/14/3932.full.pdf
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review, Br J Haematol. mai, vol.165, issue.3, pp.273-86, 2014. ,
DOI : 10.1111/bjh.12756
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12756
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms, Hematol Oncol Clin North Am, vol.26, issue.5, pp.1053-64, 2012. ,
RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant ,
, Clin Cancer Res Off J Am Assoc Cancer Res. 15 avr, vol.16, issue.8, pp.2246-56, 2010.
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation, Leukemia. août, vol.23, issue.8, pp.1426-1457, 2009. ,
DOI : 10.1038/leu.2009.48
URL : https://www.nature.com/articles/leu200948.pdf
GMCSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia, Blood. 20 juin, vol.121, issue.25, pp.5068-77, 2013. ,
DOI : 10.1182/blood-2012-10-460170
URL : http://www.bloodjournal.org/content/121/25/5068.full.pdf
, Blood Journal | Clonal architecture of chronic myelomonocytic leukemias
,
ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia, Blood. 5 juin, vol.123, issue.23, pp.3675-3682, 2014. ,
DOI : 10.1182/blood-2014-03-562637
URL : http://www.bloodjournal.org/content/123/23/3675.full.pdf
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia, Blood. 28 août, vol.124, issue.9, pp.1513-1534, 2014. ,
DOI : 10.1182/blood-2014-03-560227
URL : http://www.bloodjournal.org/content/124/9/1513.full.pdf
, Leucémie myélomonocytaire chronique : diagnostic et thérapeutique-revmed
The genetic basis of myelodysplasia and its clinical relevance, Blood. 12 déc, vol.122, issue.25, pp.4021-4055, 2013. ,
DOI : 10.1182/blood-2013-09-381665
URL : http://www.bloodjournal.org/content/122/25/4021.full.pdf
International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood. 15 mars, vol.89, issue.6, pp.2079-88, 1997. ,
DOI : 10.1182/blood-2012-03-420489
URL : http://www.bloodjournal.org/content/120/12/2454.full.pdf
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients, Blood. 1 févr, vol.99, issue.3, pp.840-849, 2002. ,
New prognostic parameters for chronic myelomonocytic leukemia?, Blood. 15 juill, vol.100, issue.2, pp.731-734, 2002. ,
DOI : 10.1182/blood-2002-01-0330
URL : http://www.bloodjournal.org/content/100/2/731.full.pdf
Chronic myelomonocytic leukemia in the light of the WHO proposals, Haematologica. juill, vol.92, issue.7, pp.974-981, 2007. ,
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia, Blood. 11 avr, vol.121, issue.15, pp.3005-3020, 2013. ,
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes, Leukemia. juill, vol.27, issue.7, pp.1504-1514, 2013. ,
DOI : 10.1038/leu.2013.88
URL : https://www.nature.com/articles/leu201388.pdf
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients, Leukemia. nov, vol.28, issue.11, pp.2206-2218, 2014. ,
Prognostic score including gene mutations in chronic myelomonocytic leukemia, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.31, pp.2428-2464, 2013. ,
,
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review, Br J Haematol. mai, vol.165, issue.3, pp.273-86, 2014. ,
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol. mars, vol.10, issue.3, pp.223-255, 2009. ,
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study, Leuk Lymphoma. mars, vol.54, issue.3, pp.658-61, 2013. ,
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine, Leuk Res. juin, vol.37, issue.6, pp.609-622, 2013. ,
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients, Blood, vol.124, issue.17, pp.2705-2717, 2014. ,
Nomenclature of monocytes and dendritic cells in blood, Blood, vol.116, issue.16, pp.74-80, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00611173
Blood monocytes consist of two principal subsets with distinct migratory properties, Immunity. juill, vol.19, issue.1, pp.71-82, 2003. ,
The routine leukocyte differential flow cytometry HematoFlow TM method: A new flagging system for automatic validation ,
, Cytometry B Clin Cytom, vol.88, issue.6, pp.375-84, 2015.
Refining the white blood cell differential: The first flow cytometry routine application, Cytometry A. 1 juin, vol.77, issue.6, pp.552-63, 2010. ,
Molecular basis of CD36 deficiency. Evidence that a 478C->T substitution (proline90->serine) in CD36 cDNA accounts for CD36 deficiency, J Clin Invest. mars, vol.95, issue.3, pp.1040-1046, 1995. ,
, , p.1
, CA) as part of the complete blood count (CBC) workflow. 2,3 The HF uses a cocktail of antibodies, including CD36 and CD16, to report a 5-part differential and cell subsets such as CD16 pos-and CD16 neg-monocyte. Here, we would like to report our experience in identifying CMML patients with the %CD16 neg Mo, on the basis of a regular CBC, We read with interest the article by Selimoglu-Buet and colleagues validating the fraction of CD16 neg-monocytes
, 08-2.33) for CMML and control groups, respectively. We found an optimal %CD16 neg Mo cutoff at 94% to discriminate CMML from control patients (sensitivity at 70.45%, specificity at 88.17% and area under the curve
Characteristic repartition of ,
Refining the white blood cell differential: the first flow cytometry routine application, Cytometry A, vol.77, issue.6, pp.552-563, 2010. ,
Toward a reference method for leukocyte differential counts in blood: Comparison of three flow cytometric candidate methods, Cytometry A ,
Improvement of the leukocyte differential performed by flow cytometry using the advanced 2.0 version of the CytoDiff CXP software ,
URL : https://hal.archives-ouvertes.fr/hal-01060858
, Cytometry A, vol.85, issue.8, pp.653-657, 2014.